Investigational Drug Information for LB1148
✉ Email this page to a colleague
What is the development status for investigational drug LB1148?
LB1148 is an investigational drug.
There have been 6 clinical trials for LB1148.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 28th 2022.
The most common disease conditions in clinical trials are Tissue Adhesions, Ileus, and Digestive System Diseases. The leading clinical trial sponsors are Leading BioSciences, Inc, Ronald Hurst, MD, FACS, and Newsoara Biopharma Co., Ltd.
There are fifty-six US patents protecting this investigational drug and zero international patents.
Summary for LB1148
| US Patents | 56 |
| International Patents | 1,636 |
| US Patent Applications | 904 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 5,700 |
| Clinical Trial Progress | Phase 2 (2022-06-28) |
| Vendors | 86 |
Recent Clinical Trials for LB1148
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection | Palisade Bio | Phase 3 |
| LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia | Leading BioSciences, Inc | Phase 2 |
| A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection | Leading BioSciences, Inc | Phase 2 |
Clinical Trial Summary for LB1148
Top disease conditions for LB1148
Top clinical trial sponsors for LB1148
US Patents for LB1148
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LB1148 | ⤷ Sign Up | Phosphonate compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Sign Up |
| LB1148 | ⤷ Sign Up | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) | ⤷ Sign Up |
| LB1148 | ⤷ Sign Up | Methods for making ribosomes | Northwestern University (Evanston, IL) | ⤷ Sign Up |
| LB1148 | ⤷ Sign Up | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | The Regents of the University of California (Oakland, CA) | ⤷ Sign Up |
| LB1148 | ⤷ Sign Up | Alkyl cellulose for use in tableting and solid preparation comprising same | Shin-Etsu Chemical Co., Ltd. (Tokyo, JP) | ⤷ Sign Up |
| LB1148 | ⤷ Sign Up | Anti-radical agents | BASF SE (Ludwigshafen, DE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LB1148
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LB1148 | Taiwan | TW201718611 | 2035-08-26 | ⤷ Sign Up |
| LB1148 | World Intellectual Property Organization (WIPO) | WO2017035357 | 2035-08-26 | ⤷ Sign Up |
| LB1148 | World Intellectual Property Organization (WIPO) | WO2014052836 | 2032-09-27 | ⤷ Sign Up |
| LB1148 | Australia | AU2014296261 | 2033-07-31 | ⤷ Sign Up |
| LB1148 | Brazil | BR112016001600 | 2033-07-31 | ⤷ Sign Up |
| LB1148 | Canada | CA2918242 | 2033-07-31 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
